Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. peru. med. exp. salud publica ; 30(4): 601-607, oct.-dic. 2013. ilus, tab
Artigo em Espanhol | LILACS, LIPECS | ID: lil-698119

RESUMO

Objetivos. Determinar la eficacia en dosis única del albendazol sobre las infecciones por helmintos transmitidos por el suelo (HTS) en escolares de una comunidad de la ciudad de Iquitos en Perú. Materiales y métodos. Dentro del contexto de un ensayo controlado aleatorizado realizado en una comunidad periurbana de escasos recursos, situada en Iquitos, en la Amazonía de Perú, se obtuvieron muestras de heces de escolares del quinto grado de primaria en 18 escuelas y se analizó la prevalencia y la intensidad de HTS. Un total de 1193 escolares fueron desparasitados con albendazol en dosis única (400 mg). De los 909 escolares que fueron encontrados positivos con al menos una infección por HTS, una muestra aleatoria de 385 fue seguida dos semanas más tarde, cuando se recolectó y analizó una segunda muestra de heces. Resultados. La eficacia del albendazol fue satisfactoria para las infecciones por Ascaris lumbricoides con una tasa de reducción de huevos (TRH) de 99,8%; IC 95: 99,3-100 y por anquilostomideos con una TRH de 93,6%, IC 95%: 88,2-96,6 y por Trichuris trichiura con una TRH de 72,7%, IC 95: 58,5-79,1. Conclusiones. Estos resultados son indicativos de niveles satisfactorios de eficacia y son congruentes con datos publicados sobre la eficacia del albendazol y directivas de la Organización Mundial de la Salud. Futuras investigaciones deben centrarse en mejorar la eficacia de las estrategias de tratamiento para la infección por Trichuris trichiura.


Objectives. To determine the efficacy of single-dose albendazole (400 mg) for soil-transmitted helminth infections (STH) in schoolchildren living in one community of the city of Iquitos, Perú. Materials and methods. Within the context of a randomized controlled trial performed in a peri-urban community of limited resources located in Iquitos in the Peruvian Amazon, stool specimens were collected from Grade 5 schoolchildren in 18 schools and analysed for STH prevalence and intensity. A total of 1,193 school-age children were then dewormed with single-dose albendazole (400 mg). Of the 909 children who were found positive with at least one STH infection, a random sample of 385 was followed two weeks later when a second stool specimen was collected and analyzed. Results. The efficacy of albendazole was satisfactory: for Ascaris lumbricoides , with an egg reduction rate (ERR) of 99.8%; (95% CI: 99.3-100); for hookworm, with an ERR of 93.6 %; (95% CI: 88.2-96.6) and, for Trichuris trichiura, with an ERR of 72.7 %; (95% CI: 58.5-79.1). Conclusions. These results are consistent with previous data published on the efficacy of albendazole and the directives of the World Health Organization. Future research should focus on improving the efficacy of the treatment strategies for Trichuris trichiura infection.


Assuntos
Criança , Feminino , Humanos , Masculino , Albendazol/administração & dosagem , Anti-Helmínticos/administração & dosagem , Helmintíase/tratamento farmacológico , Helmintíase/transmissão , Meio Ambiente , Peru , Instituições Acadêmicas , Solo/parasitologia
2.
Rev Peru Med Exp Salud Publica ; 30(4): 601-7, 2013.
Artigo em Espanhol | MEDLINE | ID: mdl-24448936

RESUMO

OBJECTIVES: To determine the efficacy of single-dose albendazole (400 mg) for soil-transmitted helminth infections (STH) in schoolchildren living in one community of the city of Iquitos, Perú. MATERIALS AND METHODS: Within the context of a randomized controlled trial performed in a peri-urban community of limited resources located in Iquitos in the Peruvian Amazon, stool specimens were collected from Grade 5 schoolchildren in 18 schools and analysed for STH prevalence and intensity. A total of 1,193 school-age children were then dewormed with single-dose albendazole (400 mg). Of the 909 children who were found positive with at least one STH infection, a random sample of 385 was followed two weeks later when a second stool specimen was collected and analyzed. RESULTS: The efficacy of albendazole was satisfactory: for Ascaris lumbricoides , with an egg reduction rate (ERR) of 99.8%; (95% CI: 99.3-100); for hookworm, with an ERR of 93.6 %; (95% CI: 88.2-96.6) and, for Trichuris trichiura, with an ERR of 72.7 %; (95% CI: 58.5-79.1). CONCLUSIONS: These results are consistent with previous data published on the efficacy of albendazole and the directives of the World Health Organization. Future research should focus on improving the efficacy of the treatment strategies for Trichuris trichiura infection.


Assuntos
Albendazol/administração & dosagem , Anti-Helmínticos/administração & dosagem , Helmintíase/tratamento farmacológico , Helmintíase/transmissão , Criança , Meio Ambiente , Feminino , Humanos , Masculino , Peru , Instituições Acadêmicas , Solo/parasitologia
3.
PLoS One ; 6(9): e24517, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21931737

RESUMO

BACKGROUND: In the development of HIV vaccines, improving immunogenicity while maintaining safety is critical. Route of administration can be an important factor. METHODOLOGY/PRINCIPAL FINDINGS: This multicenter, open-label, randomized trial, HVTN 069, compared routes of administration on safety and immunogenicity of a DNA vaccine prime given intramuscularly at 0, 1 and 2 months and a recombinant replication-defective adenovirus type 5 (rAd5) vaccine boost given at 6 months by intramuscular (IM), intradermal (ID), or subcutaneous (SC) route. Randomization was computer-generated by a central data management center; participants and staff were not blinded to group assignment. The outcomes were vaccine reactogenicity and humoral and cellular immunogenicity. Ninety healthy, HIV-1 uninfected adults in the US and Peru, aged 18-50 were enrolled and randomized. Due to the results of the Step Study, injections with rAd5 vaccine were halted; thus 61 received the booster dose of rAd5 vaccine (IM: 20; ID:21; SC:20). After the rAd5 boost, significant differences by study arm were found in severity of headache, pain and erythema/induration. Immune responses (binding and neutralizing antibodies, IFN-γ ELISpot HIV-specific responses and CD4+ and CD8+ T-cell responses by ICS) at four weeks after the rAd5 booster were not significantly different by administration route of the rAd5 vaccine boost (Binding antibody responses: IM: 66.7%; ID: 70.0%; SC: 77.8%; neutralizing antibody responses: IM: 11.1%; ID: 0.0%; SC 16.7%; ELISpot responses: IM: 46.7%; ID: 35.3%; SC: 44.4%; CD4+ T-cell responses: IM: 29.4%; ID: 20.0%; SC: 35.3%; CD8+ T-cell responses: IM: 29.4%; ID: 16.7%; SC: 50.0%.) CONCLUSIONS/SIGNIFICANCE: This study was limited by the reduced sample size. The higher frequency of local reactions after ID and SC administration and the lack of sufficient evidence to show that there were any differences in immunogenicity by route of administration do not support changing route of administration for the rAd5 boost. TRIAL REGISTRATION: ClinicalTrials.gov NCT00384787.


Assuntos
Vacinas contra a AIDS/uso terapêutico , Adenoviridae/genética , DNA/genética , Infecções por HIV/prevenção & controle , HIV/genética , Vacinas de DNA/uso terapêutico , Adolescente , Adulto , Citocinas/metabolismo , Feminino , Vetores Genéticos , Humanos , Técnicas Imunoenzimáticas/métodos , Masculino , Pessoa de Meia-Idade , Testes de Neutralização , Plasmídeos/metabolismo , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...